Supply Chain Intelligence

BioXcel Therapeutics, Inc. Supply Chain

BTAI supply chain intelligence for BioXcel Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

BTAI ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
3Customers
2Debt Items
20Related Chains

BioXcel Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
APTUIT-OXFORD-LTD APTUIT-OXFORD-LTD 92% Drug substance is produced by Aptuit (Oxford) Ltd, an Evotec Company, and drug product by Pharma Services (Patheon) by Thermo Fisher Scientific
RODMAN-RENSHAW-LLC RODMAN-RENSHAW-LLC 92% The Company agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds from the Offering, and issue to the Placement Agent or its designees warrants to purchase a number of shar…
TLX Telix Pharmaceuticals Limited 72% Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in o…

BioXcel Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
GPOS GPOS 85% During the fourth quarter of 2022, we began contracting directly with intermediaries such as GPOs.
TMO Thermo Fisher Scientific Inc. 85% lization of our products or to produce our products in accordance with cGMP prescribed by the FDA or similar foreign requirements. Drug manufacturing facilities are subject to inspection before the F…
TMO Thermo Fisher Scientific Inc. 85% Reciprocal relationship from TMO graph: Reciprocal relationship from BTAI graph: lization of our products or to produce our products in accordance with cGMP prescribed by the FDA or similar foreign r…

BioXcel Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
BTAI-DEBT Debt stack $100.3M 90% Market cache reports total debt of $100.3M.
BTAI-DEBT-8391 Warrants outstanding: 8620000 90% xbrl warrant detail from xbrl 2025-12-31.

BioXcel Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for BioXcel Therapeutics, Inc..

BioXcel Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
BTAI-OWNER-MILLENNIUM-MANAGEMENT-LLC MILLENNIUM MANAGEMENT LLC 90% 13F overlay lists MILLENNIUM MANAGEMENT LLC as top holder; 41 tracked holders.

BioXcel Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
TLX Telix Pharmaceuticals Limited 100.00 1 ['supplier']
MXCT MaxCyte, Inc. 100.00 2
TWST Twist Bioscience Corporation 100.00 2
SOLV Solventum Corporation 100.00 2
BHP BHP Group Limited 100.00 2
IRDM Iridium Communications Inc. 100.00 2
GH Guardant Health, Inc. 100.00 2
AZTA Azenta, Inc. 100.00 2
MCRB Seres Therapeutics, Inc. 100.00 2
RY Royal Bank of Canada 100.00 2
FBIO Fortress Biotech, Inc. 100.00 2
ADCT ADC Therapeutics SA 100.00 2
IONS Ionis Pharmaceuticals, Inc. 100.00 2
BHPLF BHP Group Limited 100.00 2
CLLS Cellectis S.A. 100.00 2
ICLR ICON Public Limited Company 100.00 2
IDXG Interpace Biosciences, Inc. 100.00 2
IMTX Immatics N.V. 100.00 2
ESTA Establishment Labs Holdings Inc. 100.00 2
GPOS GPOS 54.19 1 ['receiving']
View BTAI supply chain intel →

Explore the full interactive supply chain map for BioXcel Therapeutics, Inc..

Open BTAI supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map